Al Sandrock, Biogen R&D chief (Biogen via YouTube)

Days af­ter con­tro­ver­sy greet­ed Bio­gen's block­buster Alzheimer's OK, the big biotech con­cedes a set­back on the tau front

Just days af­ter trig­ger­ing a mael­strom of con­tro­ver­sy with their de­ci­sion to launch an un­proven Alzheimer’s drug with a $56,000 price, Bio­gen $BI­IB is back with the lat­est da­ta on its mid-stage tau drug.

And it’s not good.

The big biotech says that go­suranemab — tar­get­ed at tau, the sec­ond lead­ing drug tar­get in Alzheimer’s — flat failed its Phase II and will now be tak­en out and dumped in the mass grave for all but one oth­er Alzheimer’s drug in the past gen­er­a­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.